Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 26:14:110.
doi: 10.1186/1471-2334-14-110.

Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study

Affiliations

Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study

Paul K Drain et al. BMC Infect Dis. .

Abstract

Background: A rapid diagnostic test for active tuberculosis (TB) at the clinical point-of-care could expedite case detection and accelerate TB treatment initiation. We assessed the diagnostic accuracy of a rapid urine lipoarabinomannan (LAM) test for TB screening among HIV-infected adults in a TB-endemic setting.

Methods: We prospectively enrolled newly-diagnosed HIV-infected adults (≥18 years) at 4 outpatient clinics in Durban from Oct 2011-May 2012, excluding those on TB therapy. A physician evaluated all participants and offered CD4 cell count testing. Trained study nurses collected a sputum sample for acid-fast bacilli smear microscopy (AFB) and mycobacterial culture, and performed urine LAM testing using Determine™ TB LAM in the clinic. The presence of a band regardless of intensity on the urine LAM test was considered positive. We defined as the gold standard for active pulmonary TB a positive sputum culture for Mycobacterium tuberculosis. Diagnostic accuracy of urine LAM was assessed, alone and in combination with smear microscopy, and stratified by CD4 cell count.

Results: Among 342 newly-diagnosed HIV-infected participants, 190 (56%) were male, mean age was 35.6 years, and median CD4 was 182/mm3. Sixty participants had culture-positive pulmonary TB, resulting in an estimated prevalence of 17.5% (95% CI 13.7-22.0%). Forty-five (13.2%) participants were urine LAM positive. Mean time from urine specimen collection to LAM test result was 40 minutes (95% CI 34-46 minutes). Urine LAM test sensitivity was 28.3% (95% CI 17.5-41.4) overall, and 37.5% (95% CI 21.1-56.3) for those with CD4 count <100/mm3, while specificity was 90.1% (95% CI 86.0-93.3) overall, and 86.9% (95% CI 75.8-94.2) for those with CD4 < 100/mm3. When combined with sputum AFB (either test positive), sensitivity increased to 38.3% (95% CI 26.0-51.8), but specificity decreased to 85.8% (95% CI 81.1-89.7).

Conclusions: In this prospective, clinic-based study with trained nurses, a rapid urine LAM test had low sensitivity for TB screening among newly-diagnosed HIV-infected adults, but improved sensitivity when combined with sputum smear microscopy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Participant flow diagram.
Figure 2
Figure 2
Urine LAM and sputum smear microscopy (AFB) to diagnose tuberculosis among those who were either culture-confirmed (Figure 2a) or diagnosed with clinically suspected (Figure 2b) tuberculosis. a. Culture-confirmed Pulmonary Tuberculosis (N = 60). b. Clinically Suspected Tuberculosis (N = 92). Any participant who were LAM + but not diagnosed with culture-confirmed or clinically suspected tuberculosis are not depicted in these figures.
Figure 3
Figure 3
Post-test probability of tuberculosis when using a combined screening strategy of sputum AFB and urine LAM testing for various pre-test probabilities. Column A represents a cohort with 10% prevalence of tuberculosis; columns B and C represent the baseline prevalence of culture-positive pulmonary tuberculosis (17.5%) and clinically suspected tuberculosis (26.9%) that we observed in our cohort. Column D represents a cohort with a 40% prevalence of tuberculosis, which might occur among tuberculosis suspects in a highly endemic region.

References

    1. World Health Organization. Global tuberculosis control 2011. Geneva: World Health Organization; 2011.
    1. World Health Organization. Joint TB/HIV Interventions. Geneva: World Health Organization; 2009.
    1. World Health Organization. TB/HIV Working Group. Geneva; World Health: Priority research questions for HIV/TB in HIV-prevalent and resource-limited settings; 2010.
    1. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;14(14):1875–1880. doi: 10.1097/QAD.0b013e32832e05c8. - DOI - PubMed
    1. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010;14(7):823–829. doi: 10.1086/656282. - DOI - PMC - PubMed

Publication types

MeSH terms